Which of the following is a counseling point regarding Dupilumab?

Which of the following is a counseling point regarding Dupilumab?

• A. Administered orally every day
• B. Given subcutaneously every other week
• C. Only for patients with mild asthma
• D. Used in patients > 18 years old

Answer: (B)

Dupilumab is a monoclonal antibody that functions as an interleukin-4 receptor antagonist, primarily used to treat moderate to severe asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Administered via subcutaneous injection, Dupilumab is typically dosed every two weeks, which aligns with the correct answer. This bi-weekly administration schedule is significant for managing chronic conditions as it promotes adherence to treatment while providing sustained therapeutic effect. The other aspects of Dupilumab's administration are crucial to understand, as the medication is not taken orally and it is suitable for a broader range of asthma severity, not limited to mild cases. Furthermore, while there are indications for its use based on age, Dupilumab is approved for patients aged 6 years and older in certain conditions, making the age specification less restrictive than suggested by the incorrect answer provided. Understanding the route and frequency of administration plays a vital role in educating patients about their treatment and ensuring they follow the guidelines for optimal results.

Dupilumab is a monoclonal antibody that functions as an interleukin-4 receptor antagonist, primarily used to treat moderate to severe asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Administered via subcutaneous injection, Dupilumab is typically dosed every two weeks, which aligns with the correct answer.

This bi-weekly administration schedule is significant for managing chronic conditions as it promotes adherence to treatment while providing sustained therapeutic effect. The other aspects of Dupilumab's administration are crucial to understand, as the medication is not taken orally and it is suitable for a broader range of asthma severity, not limited to mild cases. Furthermore, while there are indications for its use based on age, Dupilumab is approved for patients aged 6 years and older in certain conditions, making the age specification less restrictive than suggested by the incorrect answer provided. Understanding the route and frequency of administration plays a vital role in educating patients about their treatment and ensuring they follow the guidelines for optimal results.